Kerala HC directs Health Ministry, DoP to reply on unaffordability of patented cancer drug Ribociclib
The Kerala High Court has directed the Department of Pharmaceuticals (DoP) and a competent officer of Union Health Ministry to file their reply on the issue of unaffordability of a life-saving patented breast cancer drug, Ribociclib, within one month.
The case concerned a petitioner diagnosed with HER2- Negative Metastatic Breast Cancer who was undergoing 'targeted therapy' treatment. The monthly cost of the medicines for treatment worked out to Rs. 63,480/. However, the petitioner was receiving a monthly pension of Rs. 28000/ only, and, eventually succumbed to her illness.
For more details, check out the link given below:
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd